Orthostatic hypotension
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
all patients
eliminate aggravating factors and institute lifestyle changes
Medications that induce or aggravate orthostatic hypotension (OH; e.g., alpha-blockers, central sympatholytics such as tizanidine or methyldopa, tricyclic antidepressants, phosphodiesterase-5 inhibitors, beta-blockers) should be carefully reviewed and eliminated, if appropriate.[15]Juraschek SP, Cortez MM, Flack JM, et al. Orthostatic hypotension in adults with hypertension: a scientific statement from the American Heart Association. Hypertension. 2024 Mar;81(3):e16-30. https://www.ahajournals.org/doi/10.1161/HYP.0000000000000236 http://www.ncbi.nlm.nih.gov/pubmed/38205630?tool=bestpractice.com [18]Bhanu C, Nimmons D, Petersen I, et al. Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. PLoS Med. 2021 Nov;18(11):e1003821. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577726 http://www.ncbi.nlm.nih.gov/pubmed/34752479?tool=bestpractice.com [38]Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. https://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full http://www.ncbi.nlm.nih.gov/pubmed/23721882?tool=bestpractice.com As ‘bladder-selective’ alpha-blockers, such as tamsulosin, can aggravate OH in older men, this in turn may increase the risk of hip fracture.[42]Bird ST, Delaney JA, Brophy JM, et al. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013 Nov 5;347:f6320. http://www.bmj.com/content/347/bmj.f6320.long http://www.ncbi.nlm.nih.gov/pubmed/24192967?tool=bestpractice.com [43]Seo GH, Lee YK, Ha YC. Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry. J Bone Metab. 2015 Feb;22(1):29-32. http://e-jbm.org/DOIx.php?id=10.11005/jbm.2015.22.1.29 http://www.ncbi.nlm.nih.gov/pubmed/25774362?tool=bestpractice.com
Hypertension is a risk factor for OH, and both conditions commonly co-exist in older patients. Although certain antihypertensive agents can trigger or worsen OH, complete withdrawal of antihypertensives is not appropriate as this will lead to pressure diuresis and worsening of OH. One meta-analysis found that effective antihypertensive treatment is possible without worsening of OH.[44]Juraschek SP, Hu JR, Cluett JL, et al. Effects of intensive blood pressure treatment on orthostatic hypotension: a systematic review and individual participant-based meta-analysis. Ann Intern Med. 2021 Jan;174(1):58-68. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855528 http://www.ncbi.nlm.nih.gov/pubmed/32909814?tool=bestpractice.com Judicious use of antihypertensives (e.g., ACE inhibitors, angiotensin-II receptor antagonists) and avoiding agents likely to cause OH (e.g., alpha-blockers, central sympatholytics, beta-blockers) is recommended.
Patients should first sit when going from supine to standing. Straining during bowel movements or performing Valsalva-like manoeuvres should be avoided. Eating frequent, small meals is often effective in lessening postprandial hypotension. Patients should be aware that hot environments may worsen OH.
Physical counter-manoeuvres when upright, such as leg-crossing, standing on tiptoes, and muscle-tensing, enhance orthostatic tolerance. Custom-made, full-length elastic stockings can be useful in preventing pooling in the lower extremeties, but can be difficult to use. An abdominal binder may be as effective as a vasopressor, and can be tried first.[45]Fanciulli A, Goebel G, Metzler B, et al. Elastic abdominal binders attenuate orthostatic hypotension in Parkinson's disease. Mov Disord Clin Pract. 2015 Nov 27;3(2):156-60. http://onlinelibrary.wiley.com/doi/10.1002/mdc3.12270/full [46]Okamoto LE, Diedrich A, Baudenbacher FJ, et al. Efficacy of servo-controlled splanchnic venous compression in the treatment of orthostatic hypotension: a randomized comparison with midodrine. Hypertension. 2016 Aug;68(2):418-26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945429 http://www.ncbi.nlm.nih.gov/pubmed/27271310?tool=bestpractice.com
Patients should liberalise their dietary salt intake or use sodium chloride tablets with each meal and drink at least 2 litres of water a day.[29]Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on orthostatic hypotension. In: Gilhus NE, Barnes MP, Brainin M (eds). European Handbook of Neurological Management. Vol 1, 2nd ed. Oxford: Wiley-Blackwell; 2011. Tilting the head of the bed up during the night, by inserting blocks 15-22 cm (6-9 inches) high under the headposts, reduces overnight sodium and water excretion by the kidney and lessens OH in the morning. Another effective strategy is to rapidly drink 500 mL (16 oz) of tap water, as a fluid bolus, in 3-4 minutes. This can be used as a rescue measure for patients who are symptomatic on standing, and takes effect within 5-10 minutes, peaking at 30 minutes. This is thought to be a sympathetic reflex induced by the hypotonicity of the water rather than a volume effect.[15]Juraschek SP, Cortez MM, Flack JM, et al. Orthostatic hypotension in adults with hypertension: a scientific statement from the American Heart Association. Hypertension. 2024 Mar;81(3):e16-30. https://www.ahajournals.org/doi/10.1161/HYP.0000000000000236 http://www.ncbi.nlm.nih.gov/pubmed/38205630?tool=bestpractice.com
short-acting pressor or droxidopa
Additional treatment recommended for SOME patients in selected patient group
When non-pharmacological measures are not sufficient to alleviate symptoms, a short-acting pressor or droxidopa can be used.[38]Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. https://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full http://www.ncbi.nlm.nih.gov/pubmed/23721882?tool=bestpractice.com [50]Gales BJ, Gales MA. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8. http://www.ncbi.nlm.nih.gov/pubmed/17284509?tool=bestpractice.com [51]Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007 Jul;50(1):47-53. http://hyper.ahajournals.org/content/50/1/47.long http://www.ncbi.nlm.nih.gov/pubmed/17515448?tool=bestpractice.com [53]Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 Aug 12;108(6):724-8. http://circ.ahajournals.org/content/108/6/724.full http://www.ncbi.nlm.nih.gov/pubmed/12885750?tool=bestpractice.com Only two medications are approved for the treatment of orthostatic hypotension (OH): midodrine and droxidopa.
Vasoconstrictor agents, such as the selective alpha-1-adrenoreceptor agonist midodrine, increase blood pressure and improve symptoms of OH.[38]Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. https://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full http://www.ncbi.nlm.nih.gov/pubmed/23721882?tool=bestpractice.com Adverse effects of midodrine include pilomotor reactions, pruritus, supine hypertension, and urinary retention.[49]Chen JJ, Han Y, Tang J, et al. Standing and supine blood pressure outcomes associated with droxidopa and midodrine in patients with neurogenic orthostatic hypotension: a Bayesian meta-analysis and mixed treatment comparison of randomized trials. Ann Pharmacother. 2018 Dec;52(12):1182-1194. http://www.ncbi.nlm.nih.gov/pubmed/29972032?tool=bestpractice.com
Droxidopa, a noradrenaline prodrug, is converted to noradrenaline in the body by the same enzyme that converts levodopa to dopamine.[53]Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 Aug 12;108(6):724-8. http://circ.ahajournals.org/content/108/6/724.full http://www.ncbi.nlm.nih.gov/pubmed/12885750?tool=bestpractice.com It increases blood pressure, with a peak effect about 3 hours after administration, and improves symptoms associated with OH. It has been approved for the treatment of neurogenic OH, based upon randomised controlled trials demonstrating symptom improvement after 1 week of treatment.[54]Kaufmann H, Freeman R, Biaggioni I, et al; NOH301 Investigators. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014 Jul 22;83(4):328-35. http://www.neurology.org/content/83/4/328.long http://www.ncbi.nlm.nih.gov/pubmed/24944260?tool=bestpractice.com [55]Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015 Apr 15;30(5):646-54. http://onlinelibrary.wiley.com/doi/10.1002/mds.26086/full http://www.ncbi.nlm.nih.gov/pubmed/25487613?tool=bestpractice.com A post-marketing study to determine persistence of effects is ongoing.[56]US National Library of Medicine. ClinicalTrials.gov. Sustained effect of droxidopa in symptomatic neurogenic orthostatic hypotension (RESTORE). Dec 2021 [internet publication]. https://clinicaltrials.gov/ct2/show/NCT02586623 Droxidopa should be taken upon arising in the morning, at midday, and late afternoon at least 3 hours prior to bedtime to reduce the potential for supine hypertension. However, many patients can miss out the late afternoon dose. It may not be available in countries outside the US.
Pyridostigmine, an acetylcholinesterase inhibitor, has modest pressor effects but can help some patients with mild-to-moderate OH. It is often used in combination with midodrine.[50]Gales BJ, Gales MA. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8. http://www.ncbi.nlm.nih.gov/pubmed/17284509?tool=bestpractice.com
The noradrenaline-reuptake inhibitor atomoxetine can acutely improve upright blood pressure and ameliorate symptoms in some patients, but long-term efficacy has not been demonstrated.[51]Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007 Jul;50(1):47-53. http://hyper.ahajournals.org/content/50/1/47.long http://www.ncbi.nlm.nih.gov/pubmed/17515448?tool=bestpractice.com [52]Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014 Dec;64(6):1235-40. http://www.ncbi.nlm.nih.gov/pubmed/25185131?tool=bestpractice.com
Pressor agents are best given on an as-required basis, within the prescribed daily frequencies, taken 30-45 minutes before upright activity or meals (according to the precipitating factor for an individual patient), and their effect lasts for 2-3 hours.[38]Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. https://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full http://www.ncbi.nlm.nih.gov/pubmed/23721882?tool=bestpractice.com They should be avoided before bed.
Primary options
midodrine: 10 mg orally three times daily
OR
droxidopa: 100-600 mg orally three times daily
Secondary options
pyridostigmine: consult specialist for guidance on dose
OR
atomoxetine: consult specialist for guidance on dose
mineralocorticoid therapy
Additional treatment recommended for SOME patients in selected patient group
In non-hypertensive patients in whom non-pharmacological measures do not achieve the desired result, consideration can be given to treatment with fludrocortisone (a synthetic mineralocorticoid).[38]Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. https://onlinelibrary.wiley.com/doi/10.1111/jch.12062/full http://www.ncbi.nlm.nih.gov/pubmed/23721882?tool=bestpractice.com It is generally contraindicated in patients with heart failure - a common comorbidity of patients with orthostatic hypotension (OH).
When combined with a high salt intake, fludrocortisone raises blood pressure.[57]Hickler RB, Thompson GR, Fox LM, et al. Successful treatment of orthostatic hypotension with 9-alpha-fluorohydrocortisone. N Engl J Med. 1959 Oct 15;261:788-91. http://www.ncbi.nlm.nih.gov/pubmed/14401690?tool=bestpractice.com Evidence for fludrocortisone is, however, limited to small randomised controlled trials (of people with diabetes or Parkinson’s disease) and observational studies.[58]Veazie S, Peterson K, Ansari Y, et al. Fludrocortisone for orthostatic hypotension. Cochrane Database Syst Rev. 2021 May 17;(5):CD012868. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012868.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/34000076?tool=bestpractice.com Dietary salt can be increased or sodium chloride tablets can be taken. Water intake should be at least 2 litres each day.[29]Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on orthostatic hypotension. In: Gilhus NE, Barnes MP, Brainin M (eds). European Handbook of Neurological Management. Vol 1, 2nd ed. Oxford: Wiley-Blackwell; 2011.
Potassium supplementation may be needed, because fludrocortisone increases renal potassium excretion. Fludrocortisone should be used with extreme caution as it results in hypertension when supine, promotes cardiac fibrosis, and may accelerate progression of renal deterioration.[59]Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol. 2015 Jan;224(1):R1-13. http://joe.endocrinology-journals.org/content/224/1/R1.long http://www.ncbi.nlm.nih.gov/pubmed/25335936?tool=bestpractice.com
Primary options
fludrocortisone: 0.1 to 0.2 mg orally once daily
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer